Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
26.90
-0.20 (-0.74%)
Mar 3, 2025, 4:08 PM HKT
HKG:6826 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 2,698 | 2,645 | 2,114 | 1,750 | 1,324 | Upgrade
|
Other Revenue | - | 8.97 | 16.11 | - | - | Upgrade
|
Revenue | 2,698 | 2,654 | 2,130 | 1,750 | 1,324 | Upgrade
|
Revenue Growth (YoY) | 1.64% | 24.59% | 21.72% | 32.14% | -16.99% | Upgrade
|
Cost of Revenue | - | 796.97 | 677.45 | 490.37 | 334 | Upgrade
|
Gross Profit | 2,698 | 1,857 | 1,453 | 1,260 | 990.42 | Upgrade
|
Selling, General & Admin | - | 1,225 | 1,073 | 898.43 | 772.49 | Upgrade
|
Research & Development | - | 220.1 | 182.19 | 167.6 | 126.47 | Upgrade
|
Other Operating Expenses | 2,201 | 9.17 | 7.89 | -3.18 | -1.37 | Upgrade
|
Operating Expenses | 2,201 | 1,452 | 1,278 | 1,063 | 897.59 | Upgrade
|
Operating Income | 496.29 | 404.94 | 174.67 | 196.9 | 92.83 | Upgrade
|
Interest Expense | - | -7.29 | -7.6 | -4.96 | -4.91 | Upgrade
|
Interest & Investment Income | - | 78.87 | 92.25 | 155.75 | 144.57 | Upgrade
|
Earnings From Equity Investments | - | - | - | 2.19 | -0.13 | Upgrade
|
Currency Exchange Gain (Loss) | - | -5.61 | -2.68 | - | - | Upgrade
|
Other Non Operating Income (Expenses) | -28.54 | -2.71 | -2.78 | 32.77 | 24.66 | Upgrade
|
EBT Excluding Unusual Items | 467.75 | 468.19 | 253.86 | 382.65 | 257.03 | Upgrade
|
Impairment of Goodwill | - | - | -9.57 | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | 2.3 | -7.78 | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | 0.63 | 0.18 | - | - | Upgrade
|
Asset Writedown | - | - | -36.5 | - | - | Upgrade
|
Other Unusual Items | - | 37.14 | 35.49 | - | - | Upgrade
|
Pretax Income | 467.75 | 508.26 | 235.73 | 382.65 | 257.03 | Upgrade
|
Income Tax Expense | 47.59 | 95.99 | 45.39 | 35.37 | 30.69 | Upgrade
|
Earnings From Continuing Operations | 420.15 | 412.27 | 190.33 | 347.28 | 226.34 | Upgrade
|
Minority Interest in Earnings | - | 3.85 | -9.86 | 4.95 | 3.73 | Upgrade
|
Net Income | 420.15 | 416.12 | 180.47 | 352.23 | 230.07 | Upgrade
|
Net Income to Common | 420.15 | 416.12 | 180.47 | 352.23 | 230.07 | Upgrade
|
Net Income Growth | 0.97% | 130.58% | -48.76% | 53.10% | -37.95% | Upgrade
|
Shares Outstanding (Basic) | 233 | 334 | 340 | 345 | 347 | Upgrade
|
Shares Outstanding (Diluted) | 233 | 334 | 340 | 345 | 347 | Upgrade
|
Shares Change (YoY) | -30.17% | -1.72% | -1.47% | -0.62% | 8.72% | Upgrade
|
EPS (Basic) | 1.80 | 1.24 | 0.53 | 1.02 | 0.66 | Upgrade
|
EPS (Diluted) | 1.80 | 1.24 | 0.53 | 1.02 | 0.66 | Upgrade
|
EPS Growth | 44.59% | 134.62% | -48.00% | 54.06% | -42.93% | Upgrade
|
Free Cash Flow | - | 367.22 | -85.85 | 71.41 | 72.38 | Upgrade
|
Free Cash Flow Per Share | - | 1.10 | -0.25 | 0.21 | 0.21 | Upgrade
|
Dividend Per Share | - | 0.714 | 0.286 | 0.500 | 0.357 | Upgrade
|
Dividend Growth | - | 150.02% | -42.86% | 40.02% | -28.58% | Upgrade
|
Gross Margin | 100.00% | 69.97% | 68.20% | 71.98% | 74.78% | Upgrade
|
Operating Margin | 18.40% | 15.26% | 8.20% | 11.25% | 7.01% | Upgrade
|
Profit Margin | 15.57% | 15.68% | 8.47% | 20.13% | 17.37% | Upgrade
|
Free Cash Flow Margin | - | 13.84% | -4.03% | 4.08% | 5.46% | Upgrade
|
EBITDA | 665.04 | 573.69 | 352.62 | 332.03 | 206.21 | Upgrade
|
EBITDA Margin | 24.65% | 21.62% | 16.55% | 18.97% | 15.57% | Upgrade
|
D&A For EBITDA | 168.75 | 168.75 | 177.94 | 135.13 | 113.38 | Upgrade
|
EBIT | 496.29 | 404.94 | 174.67 | 196.9 | 92.83 | Upgrade
|
EBIT Margin | 18.40% | 15.26% | 8.20% | 11.25% | 7.01% | Upgrade
|
Effective Tax Rate | 10.17% | 18.89% | 19.26% | 9.24% | 11.94% | Upgrade
|
Revenue as Reported | - | 2,654 | 2,130 | - | - | Upgrade
|
Advertising Expenses | - | 46.04 | 37.31 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.